Ver­tex dos­es first pa­tient with next type 1 di­a­betes cell ther­a­py pro­gram, while padding its cof­fers with strong Q2

Ver­tex has dosed the first type 1 di­a­betes pa­tient with its next cell ther­a­py pro­gram, the Boston biotech said Tues­day as part of its quar­ter­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.